Bayer promoting Actron's small pill size as benefit over Orudis KT, other analgesics.
This article was originally published in The Tan Sheet
Executive Summary
BAYER EMPHASIZING ACTRON's SMALL PILL SIZE as a benefit over its competitors in press materials announcing the product's Jan. 9 launch into the analgesics market. Among the competing products facing Actron are Whitehall-Robins' Rx-to-OTC switch ketoprofen, Orudis KT, which has been on the market since November, Procter-Syntex' Aleve and other established analgesics.